Coherus Biosciences (CHRS) AI Stock Analysis

• Market Cap: $193.39M
• Dividend Yield: N/A
• Average Volume (3M): 1.08M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.19
• Revenue Growth: -72.54%
• EPS Growth: -19972.15%
• Country: US
• Employees: 228
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.31
• Shares Outstanding: 120,871,010
• 10 Day Avg. Volume: 1,558,031
• 30 Day Avg. Volume: 1,077,495
• PEG Ratio: -0.05
• Price to Book (P/B): -1.20
• Price to Sales (P/S): 0.59
• P/FCF Ratio: -7.73
• Enterprise Value/Market Cap: 0.28
• Enterprise Value/Revenue: 0.64
• Enterprise Value/Gross Profit: 1.33
• Enterprise Value/Ebitda: -0.31
• 1Y Price Target: $5.50
• Price Target Upside: 243.75% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -0.87
• Revenue Forecast (FY): $89.71M

• Rating: 52 Neutral
• Price Target: $1.50 ▼(-6.25% Downside)

The score is held back primarily by weak financial performance (sharp revenue decline, negative operating profitability, and persistently negative cash flow). Offsetting this, technicals are favorable with price above key moving averages and positive MACD, and the latest earnings call provided encouraging commercial traction and cost discipline, though execution risks in demand consistency and physician engagement remain.

Positive Factors

Commercial traction of LOQTORZI

Sustained quarter-over-quarter and year-over-year LOQTORZI sales growth indicates durable commercial adoption in oncology settings. Consistent revenue growth from a newly launched oncology asset supports scaling economics, strengthens commercial capabilities, and provides a foundation for future revenue expansion if physician uptake continues.

Improved liquidity and liability reduction

Having ~$192M of cash and a large reduction in short-term liabilities materially extends runway and reduces near-term refinancing risk. Stronger liquidity enables continued clinical development, targeted commercial investments, and strategic flexibility to pursue partnerships or weather a multi-year oncology launch cadence.

Promising novel immuno-oncology asset (tagmokitug)

Peer-reviewed data showing high selectivity and potent anti-tumor biology for tagmokitug supports a differentiated immunotherapy profile. A novel asset with translational proof of mechanism can drive durable pipeline value, attract partnerships, and diversify revenue streams beyond current franchise if clinical efficacy holds in later trials.

Negative Factors

Steep revenue decline and weak cash generation

A large trailing revenue decline combined with persistent negative operating and free cash flow undermines internal funding capacity and increases reliance on external capital. Over months, this limits the company's ability to invest in commercialization and R&D without dilutive financing or asset sales, raising execution risk.

Loss of biosimilar revenue diversification

Selling the UDENYCA and related biosimilar franchises reduces recurring, diversified revenue streams and concentrates the company on oncology launches. This increases dependence on a smaller set of products and the success of LOQTORZI and pipeline programs, amplifying revenue volatility and execution sensitivity over the medium term.

Historical leverage and profitability weakness

A history of high leverage, prior negative equity and ongoing negative operating margins constrain strategic options and heighten financial fragility. Persistent unprofitability reduces retained capital for growth, raises the probability of future financing needs, and can limit competitive investments over the coming quarters.

Coherus Biosciences Business Overview & Revenue Model

Company Description

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.

How the Company Makes Money

Coherus Biosciences generates revenue primarily through the sales of its biosimilar products, which are designed to compete with existing biologic therapies in the market. The company's key revenue streams include the commercialization of its approved biosimilars, which are sold directly to healthcare providers and pharmacies. Additionally, Coherus may engage in partnerships or licensing agreements with other biopharmaceutical companies, which can provide upfront payments, milestone payments, and royalties based on product sales. These strategic partnerships are crucial for expanding its product portfolio and accelerating market access. Furthermore, Coherus may benefit from cost savings associated with the development of biosimilars compared to original biologics, allowing for competitive pricing and improved profit margins.

Coherus Biosciences Financial Statement Overview

Summary

Coherus Biosciences is facing financial challenges with declining revenues and profitability pressures. The balance sheet shows some improvement, but historical leverage issues persist. Cash flow metrics highlight ongoing liquidity concerns.

Income Statement

Coherus Biosciences has experienced significant revenue declines in the TTM period, with a negative revenue growth rate of -41.47%. The gross profit margin has decreased from previous years, indicating pressure on profitability. Despite a positive net profit margin in the TTM period, historical data shows consistent net losses, highlighting volatility in earnings. The negative EBIT and EBITDA margins further underscore operational challenges.

Balance Sheet

The company's balance sheet shows improvement in the TTM period with a positive stockholders' equity, reducing the debt-to-equity ratio significantly. However, historical data reveals high leverage and negative equity in prior years, indicating financial instability. The return on equity remains negative, reflecting ongoing profitability challenges.

Cash Flow

Coherus Biosciences has faced consistent negative operating and free cash flows, with a declining trend in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow issues relative to earnings. Despite a positive free cash flow to net income ratio, the overall cash flow position remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	83.57M	266.96M	257.24M	211.04M	326.55M	475.82M
Gross Profit	39.94M	149.41M	98.25M	140.96M	268.96M	438.16M
EBITDA	-171.31M	60.94M	-193.94M	-255.58M	-260.69M	161.84M
Net Income	154.97M	28.51M	-237.89M	-291.75M	-287.10M	132.24M
Balance Sheet
Total Assets	516.52M	448.53M	629.60M	480.85M	679.33M	841.65M
Cash, Cash Equivalents and Short-Term Investments	191.66M	125.99M	117.75M	191.68M	417.19M	541.16M
Total Debt	40.69M	269.90M	480.84M	480.42M	419.02M	417.10M
Total Liabilities	428.75M	580.52M	823.03M	618.26M	581.61M	560.67M
Stockholders Equity	87.77M	-131.99M	-193.43M	-137.42M	97.73M	280.97M
Cash Flow
Free Cash Flow	-90.19M	-20.44M	-175.17M	-243.16M	-38.72M	146.91M
Operating Cash Flow	-90.19M	-20.44M	-174.88M	-241.12M	-37.43M	154.15M
Investing Cash Flow	377.38M	230.32M	144.64M	-166.85M	-138.41M	-14.40M
Financing Cash Flow	-281.56M	-186.97M	69.60M	54.33M	51.88M	223.95M

Coherus Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CHRS, the sentiment is Positive. The current price of 1.6 is above the 20-day moving average (MA) of 1.44, above the 50-day MA of 1.36, and above the 200-day MA of 1.16, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 59.62 is Neutral, neither overbought nor oversold. The STOCH value of 70.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CHRS.

Coherus Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PLX	59 Neutral	$165.67M	29.64	12.64%	―	35.42%	―
SLS	56 Neutral	$585.44M	-14.33	-84.33%	―	―	59.04%
CHRS	52 Neutral	$193.39M	-1.01	―	―	-72.54%	-19972.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MCRB	50 Neutral	$145.47M	26.49	15.95%	―	448.44%	―
IPHA	49 Neutral	$164.68M	-2.93	-271.32%	―	-75.77%	-31.24%

Coherus Biosciences Corporate Events

Coherus Biosciences Divests UDENYCA Business

On April 11, 2025, Coherus Biosciences sold its UDENYCA business, marking a significant divestiture of its biosimilar businesses, which included the UDENYCA, YUSIMRY, and CIMERLI franchises. This strategic shift led to the reclassification of these businesses as discontinued operations in their financial reports, reflecting a focus on their innovative oncology pipeline and the expansion of LOQTORZI sales.

The most recent analyst rating on (CHRS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Coherus Biosciences stock, see the CHRS Stock Forecast page.